Amicus Therapeutics CEO sells shares worth $87,495 By Investing.com

Amicus (NASDAQ:) Therapeutics, Inc. (NASDAQ:FOLD) has seen a notable event from the President and CEO, Bradley L. Campbell, when he sold 7,500 shares of common stock at prices ranging from $11.53 to $11.76, by weight. price of $ 11.6661, according to the latest SEC filings. Total shares sold by Campbell amounted to $87,495.

The sale took place on April 1, 2024, and was part of a planned 10b5-1 plan, which allows company insiders to set up a prearranged plan to buy or sell a company’s stock. The plan was approved by Campbell on August 23, 2023, indicating that the sale was planned in advance and not based on immediate, unknown information that could affect the company’s value.

In addition to the sale, Campbell also acquired 7,500 shares of a Amicus Therapeutics through stock options, with each option having a premium price of $8.61. The total cost of these transactions was $64,574. As noted in the SEC filing, all options were fully vested and exercisable as of the exercise date.

Following this, Campbell’s ownership in the company is 886,654 shares of common stock held directly. Sales and options transactions were conducted in accordance with SEC regulations, and all information about the number of shares sold at each price range within the stated range is available upon request.

Investors often monitor internal affairs because they can provide information about how top management views the company’s value and future prospects. Amicus Therapeutics, headquartered in Philadelphia, Pennsylvania, specializes in drug development and continues to be involved in the biotechnology industry.

InvestingPro Insights

Amicus Therapeutics, Inc. (NASDAQ:FOLD) has been focused on following the internal affairs of President and CEO, Bradley L. Campbell. Based on these trends, it is important to note some financial metrics and analysis from InvestingPro that can affect the way they earn money.

One of Amicus Therapeutics’ most notable features is its own the greatest benefitwhich was boldly stated 90.65% for the last twelve months as Q4 2023. This shows the company’s strong ability to manage its cost of goods sold and maintain profit on its products. Also, the company money growth for the same period 21.3%showing its additional functions.

However, the company is currently not profitable, and negative P/E ratio about -22.08and the adjusted P/E ratio for the last twelve months as of Q4 2023 stands at -24.62. This highlights the challenges Amicus Therapeutics faces in making any profit despite its large capital base.

From a financial perspective, Amicus Therapeutics is trading at a high / multiple Book value 20.97, which would suggest that the stock is undervalued relative to the company’s book value. This metric, including that 2 researchers have revised their findings below for the time to come, it could be a concern for potential investors.

For those who want to know more, there are more InvestingPro Tips findings that can provide more information about the company’s financial situation and future prospects. For example, Amicus Therapeutics operates with limited debt and its liquid assets exceed those of the short-term, which reflects the current state of the economy. Also, experts predict that the company will be profitable this year, which could be a turning point for the company.

To dive deeper into Amicus Therapeutics and get exclusive analysis, consider subscribing to InvestingPro. Use the coupon code PRONEWS24 to receive an additional 10% on annual or bi-annual Pro and Pro+ subscriptions. With this subscription, you will get access to financial information and information, including a complete list of InvestingPro Instructions which will help you make informed business decisions.

This article was created with the help of AI and reviewed by an editor. For more information see our T&C.

!function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function(){n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)};if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version=’2.0′;n.queue=[];t=b.createElement(e);t.async=!0;t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,’script’,’https://connect.facebook.net/en_US/fbevents.js’);



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *